Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized furosemide for acute exacerbation of chronic obstructive pulmonary disease
PACTR202410667497756Phase 4Recruiting
- Sponsor
- hela Ben Turkia
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Furosemide group with Placebo group (2 arms). Primary endpoint: Improvement in forced expiratory volume in one second. Started Oct 2024; status: recruiting.
02
Drugs
furosemide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on PACTR202410667497756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202410667497756.